Eshe Nelson
- Indexed articles, last 90 days
- 1
- Latest publication
- Sep 3, 2026
- Outlet visibility, for Brisbane Times
- Top 100K sites
- Earliest in this view
- Sep 3, 2026
Latest articles
Ozempic’s maker is in trouble. Tablets may be the answer (opens the original)
Read excerpt
For Novo Nordisk, the Danish drugmaker behind Ozempic and Wegovy, the release of its weight-loss pill has been a much-needed triumph. It was a scientific breakthrough to make an effective tablet form of Wegovy, a weekly injection. It was also a commercial success: More than 1.5 million people, mostly in the United States, have started taking the daily pill since it became available in January. But the company’s investors have not been dazzled. They are nervously looking further into the future.
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 100K sites
For Brisbane Times, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.